R13 (drug)

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Other names4-Oxo-2-phenyl-4H-chromene-7,8-diyl bis(methylcarbamate)
Routes of
By mouth[1]
Pharmacokinetic data
PubChem CID
Chemical and physical data
Molar mass368.345 g/mol g·mol−1
3D model (JSmol)

R13 is a small-molecule flavonoid and orally active, potent, and selective agonist of the tropomyosin receptor kinase B (TrkB) – the main signaling receptor for the neurotrophin brain-derived neurotrophic factor (BDNF) – which is under development for the potential treatment of Alzheimer's disease.[1][2] It is a structural modification and prodrug of 7,8-dihydroxyflavone (7,8-DHF) with improved potency and pharmacokinetics, namely oral bioavailability and duration.[1] The compound is a replacement for the earlier 7,8-DHF prodrug R7 and has similar properties to it.[1][3] It was developed because while R7 displayed a good drug profile in animal studies, it showed almost no conversion into 7,8-DHF in human liver microsomes.[1] In contrast to R7, R13 is readily hydrolyzed into 7,8-DHF in human liver microsomes.[1]

See also[edit]


  1. ^ a b c d e f g Chen C, Wang Z, Zhang Z, Liu X, Kang SS, Zhang Y, Ye K (January 2018). "The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer's disease". Proc. Natl. Acad. Sci. U.S.A. 115 (3): 578–583. doi:10.1073/pnas.1718683115. PMC 5777001. PMID 29295929.
  2. ^ US application 20150274692, Keqiang Ye, "7,8-Dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto", published 2015-10-01, assigned to Emory University 
  3. ^ Liu C, Chan CB, Ye K (2016). "7,8-dihydroxyflavone, a small molecular TrkB agonist, is useful for treating various BDNF-implicated human disorders". Transl Neurodegener. 5: 2. doi:10.1186/s40035-015-0048-7. PMC 4702337. PMID 26740873.

External links[edit]